| Apixaban and pharmaceutical acceptable salts thereof |
2023-8-17 |
2023-8-17 |
|
| AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 … |
2023-8-14 |
2023-10-13 |
|
| Tumor treatment method using anti-PD-1 antibody |
2023-8-04 |
2023-10-31 |
|
| Macrocycles as Factor XIA Inhibitors with Heterocyclic P2' Groups |
2023-8-01 |
2023-9-22 |
|
| Pyrimidinone as a factor XIA inhibitor |
2023-7-19 |
2023-9-27 |
|
| Treatment of LAG-3 positive tumors |
2023-7-06 |
2023-10-03 |
|
| Antibodies against TIGIT |
2023-7-06 |
2023-10-03 |
|
| Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway … |
2023-7-06 |
2023-9-12 |
|
| Anti-LAG-3 antibody or composition comprising anti-LAG-3 antibody and anti-PD-1 … |
2023-6-20 |
2023-9-27 |
|
| 6-amino-7,9-dihydro-8H-purin-8-one derivatives as toll-like receptor 7 (TLR7) … |
2023-6-05 |
2023-8-16 |
|
| Triazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists |
2023-5-22 |
2023-10-26 |
|
| Retalimab - extended SPC |
2023-5-03 |
2023-5-03 |
|
| [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
2023-4-26 |
2023-8-17 |
|
| Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl- … |
2023-4-13 |
2023-8-31 |
|
| Quinazolines as potassium ion channel inhibitors |
2023-3-24 |
2023-10-12 |
|
| ENHANCED ANTICANCER ACTIVITY OF IMMUNOMODULATORY Fc FUSION PROTEINS |
2023-3-22 |
2023-6-06 |
|
| Antagonistic CD40 Monoclonal Antibodies and Uses Thereof |
2023-3-10 |
2023-10-12 |
|
| PSGL-1 antagonists and uses thereof |
2023-3-08 |
2023-6-27 |
|
| Indole carboxamide compounds |
2023-2-23 |
2023-6-22 |
|
| Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
2023-2-03 |
2023-3-02 |
|
| Use of ADCC-Enhanced Anti-CTLA-4 Antibodies to Enhance Immune Responses to … |
2023-2-03 |
2023-4-18 |
|
| Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h- … |
2023-1-29 |
2023-8-03 |
|
| Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4- … |
2023-1-20 |
2023-6-01 |
|
| Antibodies binding to vista at acidic ph |
2023-1-12 |
2023-5-02 |
|
| combination therapy for cancer |
2022-12-23 |
2023-4-11 |
|
| 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS … |
2022-12-14 |
2023-5-04 |
|
| Methods of treating tumor |
2022-12-07 |
2023-9-21 |
|
| Glypican-3-binding fibronectin based scaffold molecules |
2022-11-10 |
2023-10-05 |
|
| METHODS OF USING CTLA4Ig SUBCUTANEOUS FORMULATIONS |
2022-11-03 |
2023-9-07 |
|
| Method of treating cancer using immune checkpoint inhibitor |
2022-10-21 |
2023-2-21 |
|
| Methods of treating tumor |
2022-10-17 |
2023-9-21 |
|
| Modified FGF-21 Polypeptides and Uses Thereof |
2022-10-13 |
2022-11-03 |
|
| 6-amino-7,9-dihydro-8h-purin-8-one derivatives as immunostimulant toll-like … |
2022-10-12 |
2023-1-24 |
|
| Antibodies comprising modified heavy chain constant regions |
2022-10-04 |
2023-1-24 |
|
| Use of anti-pd-1 antibody in treatment of patients with colorectal cancer |
2022-9-29 |
2023-1-10 |
|
| Antibodies to cd40 |
2022-9-08 |
2022-11-10 |
|
| Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
2022-9-06 |
2023-8-03 |
2023-8-03 |
| Imidazothiadiazole and imidazopyrazine derivatives as protease activated … |
2022-9-02 |
2023-8-03 |
|
| Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses … |
2022-8-16 |
2022-11-03 |
|
| Fibronectin based scaffold proteins |
2022-8-16 |
2023-8-03 |
|
| Antibodies against ox-40 and uses thereof |
2022-8-11 |
2023-8-31 |
|
| CGRP RECEPTOR ANTAGONISTS |
2022-8-11 |
2022-9-30 |
|
| Treatment of lung cancer using a combination of an anti-pd-1 antibody and … |
2022-8-08 |
2023-3-16 |
|
| Tumor necrosis factor-like ligand 1a specific antibodies and compositions and … |
2022-7-28 |
2022-12-08 |
|
| Fast-off rate serum albumin binding fibronectin type iii domains |
2022-7-25 |
2023-5-11 |
|
| Fibronectin binding domains with reduced immunogenicity |
2022-7-18 |
2023-6-15 |
|
| Stabilized fibronectin based scaffold molecules |
2022-7-18 |
2023-6-22 |
|
| 6-azaindole compounds |
2022-6-30 |
2022-11-03 |
|
| Compositions comprising a combination of an anti-pd-1 antibody and another … |
2022-6-10 |
2022-6-30 |
|
| Apelin receptor agonists and methods of use |
2022-6-09 |
2022-10-06 |
|
| Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
2022-5-13 |
2022-11-03 |
|
| Carbamoyloxymethyltriazole cyclohexylates as LPA antagonists |
2022-5-11 |
2023-7-20 |
2023-7-20 |
| Antibodies against cd73 and uses thereof |
2022-5-05 |
2023-2-16 |
|
| Treatment of renal cancer using a combination of an anti-pd-1 antibody and … |
2022-5-04 |
2022-12-08 |
|
| Immunomodulators |
2022-4-20 |
2023-3-30 |
|
| Anti-pd-1 antibody in combination with an anti-cd30 antibody in cancer … |
2022-4-07 |
2022-9-22 |
|
| Pet imaging with pd-l1 binding polypeptides |
2022-4-04 |
2022-11-03 |
|
| Combination therapy using anti-cd73 antibody |
2022-3-30 |
2022-7-12 |
|
| Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
2022-3-22 |
2022-9-08 |
|
| Anti-pd-1 antibody for use in a method of treating a tumor |
2022-3-21 |
2022-10-06 |
|
| Substituted indole compounds |
2022-3-21 |
2023-3-30 |
|
| Activatable anti-ctla-4 antibodies and uses thereof |
2022-3-09 |
2022-6-21 |
|
| Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
2022-2-25 |
2022-5-13 |
|
| Anti-lag-3 antibodies for treating hematological malignancies |
2022-2-25 |
2022-5-09 |
|
| Cation exchange chromatography methods |
2022-2-24 |
2022-6-09 |
|
| Antibodies against tim3 and uses thereof |
2022-2-16 |
2022-5-24 |
|
| Anti-nkg2a antibodies and uses thereof |
2022-2-11 |
2022-6-30 |
|
| Antagonistic cd40 monoclonal antibodies and uses thereof |
2022-2-11 |
2022-6-02 |
|
| Methods of treating systemic lupus erythematosus using a domain antibody … |
2022-1-25 |
2022-5-12 |
|
| Antibody heavy chain constant domains |
2022-1-07 |
2022-6-16 |
|
| SPIROHEPTANIUM SALICYLAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS |
2021-12-09 |
2022-11-25 |
|
| Methods and compositions for 18f-radiolabeling of biologics |
2021-12-01 |
2022-6-16 |
|
| Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) … |
2021-11-19 |
2022-6-09 |
|
| Serum albumin-binding fibronectin type iii domains |
2021-11-16 |
2022-6-30 |
|
| Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti- … |
2021-11-10 |
2022-5-05 |
|
| Antibody polypeptides that antagonize cd40l |
2021-11-09 |
2022-3-10 |
|
| NOVEL TRICYCLIC COMPOUNDS AS ANTINEOPLASTIC AGENTS |
2021-11-03 |
2023-2-01 |
|
| THIENOPYRIDINES AND BENZOTHIOPHENIES USED AS IRAK4 INHIBITORS |
2021-10-07 |
2022-7-22 |
|
| Macrocycles as factor xia inhibitors |
2021-10-04 |
2023-2-23 |
|
| Fibronectin based scaffold proteins having improved stability |
2021-9-29 |
2022-4-21 |
|
| Novel pd-l1 binding polypeptides for imaging |
2021-9-23 |
2022-1-06 |
|
| Heteroaryl compounds useful as MK2 inhibitors |
2021-9-17 |
2023-9-19 |
2023-9-19 |
| Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs |
2021-9-03 |
2022-6-23 |
|
| Pet-imaging immunomodulators |
2021-8-26 |
2021-12-16 |
|
| Bispecific antibodies against CD3epsilon and BCMA for use in treatment of … |
2021-8-25 |
2021-9-23 |
|
| Heterocyclic compounds and uses thereof |
2021-8-20 |
2022-7-14 |
|
| Use of immune checkpoint inhibitors in central nervous system neoplasms |
2021-8-12 |
2021-11-25 |
|
| Phenylpyrrolidinone formyl peptide 2 receptor agonists |
2021-8-12 |
2023-7-25 |
2023-7-25 |
| Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
2021-7-28 |
2022-3-31 |
|
| Treatment of lung cancer using a combination of an anti-pd-1 antibody and an … |
2021-7-26 |
2022-1-20 |
|
| Binding molecules to the human ox40 receptor |
2021-7-13 |
2022-1-06 |
|
| Treatment of renal cell carcinoma |
2021-7-09 |
2022-1-06 |
|
| Method of treating lung cancer |
2021-7-08 |
2023-9-26 |
2023-9-26 |
| Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) … |
2021-6-30 |
2023-2-16 |
|
| Bispecific antibody against bcma and cd3 and an immunological drug for combined … |
2021-6-24 |
2022-1-20 |
|
| Fibronectin based scaffold domain proteins that bind to myostatin |
2021-6-23 |
2021-9-17 |
|
| Lactam, cyclic urea and carbamate, and triazolone derivatives, as potent and … |
2021-6-23 |
2021-9-30 |
|
| 5-membered and bicyclic heterocyclic amides as inhibitors of rock |
2021-6-17 |
2022-11-10 |
|
| Pyrimidinones as factor xia inhibitors |
2021-6-15 |
2022-2-10 |
|
| Methods for the selection of binding proteins |
2021-6-08 |
2021-12-30 |
|